HeraMED Statistics

Total Valuation

HeraMED has a market cap or net worth of AUD 14.01 million. The enterprise value is 10.93 million.

Market Cap	14.01M
Enterprise Value	10.93M

Important Dates

The next estimated earnings date is Wednesday, May 28, 2025.

Earnings Date	May 28, 2025
Ex-Dividend Date	n/a

Share Statistics

HeraMED has 875.60 million shares outstanding. The number of shares has increased by 104.15% in one year.

Current Share Class	n/a
Shares Outstanding	875.60M
Shares Change (YoY)	+104.15%
Shares Change (QoQ)	+92.88%
Owned by Insiders (%)	10.73%
Owned by Institutions (%)	7.72%
Float	680.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	38.45
PB Ratio	5.06
P/TBV Ratio	5.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.99
EV / Sales	29.99
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.52, with a Debt / Equity ratio of 0.03.

Current Ratio	3.52
Quick Ratio	3.12
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-112.88

Financial Efficiency

Return on equity (ROE) is -317.64% and return on invested capital (ROIC) is -179.33%.

Return on Equity (ROE)	-317.64%
Return on Assets (ROA)	-91.62%
Return on Invested Capital (ROIC)	-179.33%
Return on Capital Employed (ROCE)	-158.93%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.10
Inventory Turnover	0.40

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.57% in the last 52 weeks. The beta is 0.28, so HeraMED's price volatility has been lower than the market average.

Beta (5Y)	0.28
52-Week Price Change	-8.57%
50-Day Moving Average	0.02
200-Day Moving Average	0.02
Relative Strength Index (RSI)	52.97
Average Volume (20 Days)	540,536

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HeraMED had revenue of AUD 364,328 and -5.49 million in losses. Loss per share was -0.01.

Revenue	364,328
Gross Profit	218,582
Operating Income	-5.45M
Pretax Income	-5.49M
Net Income	-5.49M
EBITDA	-5.41M
EBIT	-5.45M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 3.17 million in cash and 82,089 in debt, giving a net cash position of 3.08 million or 0.00 per share.

Cash & Cash Equivalents	3.17M
Total Debt	82,089
Net Cash	3.08M
Net Cash Per Share	0.00
Equity (Book Value)	2.77M
Book Value Per Share	0.00
Working Capital	2.66M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-4.81M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	60.00%
Operating Margin	-1,496.29%
Pretax Margin	-1,507.04%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

HeraMED does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-104.15%
Shareholder Yield	-104.15%
Earnings Yield	-39.19%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HeraMED has an Altman Z-Score of -13.58. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.58
Piotroski F-Score	n/a